Douglass Winthrop Advisors LLC trimmed its position in Illumina, Inc. (NASDAQ:ILMN) by 12.1% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,762 shares of the life sciences company’s stock after selling 518 shares during the quarter. Douglass Winthrop Advisors LLC’s holdings in Illumina were worth $1,381,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Cadence Capital Management LLC lifted its position in shares of Illumina by 3.6% during the 2nd quarter. Cadence Capital Management LLC now owns 4,702 shares of the life sciences company’s stock valued at $1,313,000 after acquiring an additional 162 shares during the period. Sumitomo Mitsui Asset Management Company LTD lifted its position in shares of Illumina by 1.8% during the 2nd quarter. Sumitomo Mitsui Asset Management Company LTD now owns 10,241 shares of the life sciences company’s stock valued at $2,860,000 after acquiring an additional 179 shares during the period. Private Asset Management Inc. lifted its position in shares of Illumina by 1.6% during the 2nd quarter. Private Asset Management Inc. now owns 11,243 shares of the life sciences company’s stock valued at $3,140,000 after acquiring an additional 180 shares during the period. Northwestern Mutual Wealth Management Co. lifted its position in shares of Illumina by 12.9% during the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 1,627 shares of the life sciences company’s stock valued at $454,000 after acquiring an additional 186 shares during the period. Finally, Dempze Nancy E lifted its position in shares of Illumina by 3.7% during the 2nd quarter. Dempze Nancy E now owns 5,432 shares of the life sciences company’s stock valued at $1,517,000 after acquiring an additional 194 shares during the period. 89.84% of the stock is currently owned by hedge funds and other institutional investors.

In related news, EVP Marc Stapley sold 1,000 shares of the company’s stock in a transaction on Thursday, August 2nd. The stock was sold at an average price of $324.80, for a total transaction of $324,800.00. Following the completion of the sale, the executive vice president now directly owns 8,316 shares in the company, valued at approximately $2,701,036.80. The sale was disclosed in a filing with the SEC, which is available through this link. Also, Director Robert S. Epstein sold 500 shares of the company’s stock in a transaction on Monday, July 23rd. The stock was sold at an average price of $311.15, for a total value of $155,575.00. Following the sale, the director now owns 6,139 shares of the company’s stock, valued at $1,910,149.85. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 52,483 shares of company stock valued at $17,702,063. 0.54% of the stock is owned by corporate insiders.

Shares of ILMN stock opened at $321.69 on Friday. The company has a quick ratio of 2.44, a current ratio of 2.74 and a debt-to-equity ratio of 0.22. Illumina, Inc. has a twelve month low of $198.21 and a twelve month high of $372.61. The firm has a market cap of $53.96 billion, a P/E ratio of 80.42, a price-to-earnings-growth ratio of 3.04 and a beta of 0.97.

Illumina (NASDAQ:ILMN) last announced its quarterly earnings data on Monday, July 30th. The life sciences company reported $1.43 earnings per share for the quarter, topping the consensus estimate of $1.11 by $0.32. Illumina had a return on equity of 26.64% and a net margin of 20.88%. The business had revenue of $830.00 million during the quarter, compared to the consensus estimate of $786.88 million. During the same period in the prior year, the company earned $0.82 EPS. Illumina’s revenue for the quarter was up 25.4% on a year-over-year basis. On average, research analysts expect that Illumina, Inc. will post 5.46 earnings per share for the current fiscal year.

A number of research firms have recently weighed in on ILMN. UBS Group began coverage on Illumina in a research report on Tuesday. They set a “neutral” rating and a $340.00 target price for the company. Barclays upped their target price on Illumina from $300.00 to $350.00 and gave the company an “overweight” rating in a research report on Tuesday, July 31st. Citigroup upped their target price on Illumina from $330.00 to $345.00 and gave the company a “buy” rating in a research report on Tuesday, July 31st. Bank of America upped their target price on Illumina from $345.00 to $370.00 and gave the company a “buy” rating in a research report on Tuesday, July 31st. Finally, Piper Jaffray Companies upped their target price on Illumina from $272.00 to $329.00 and gave the company an “overweight” rating in a research report on Tuesday, July 17th. Five analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus price target of $324.76.

Illumina Profile

Illumina, Inc provides sequencing and array-based solutions for genetic analysis. The company operates in two segments, Core Illumina and Consolidated VIEs. It offers sequencing by synthesis technology that provides researchers with various applications and the ability to sequence mammalian genomes; and arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as allow the detection of known genetic markers on a single array.

Read More: Do You Need a Fiduciary?

Want to see what other hedge funds are holding ILMN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Illumina, Inc. (NASDAQ:ILMN).

Institutional Ownership by Quarter for Illumina (NASDAQ:ILMN)

Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.